Abstract:Abstract Abstract 2491 Background: Most studies have demonstrated NPM1-mutated acute myeloid leukemia(NPM1m+AML) has a favorable prognosis, especially in the absence of concomitant FLT3-ITD. However, recent studies showed the prognostic heterogeneity of NPM1m+AML. CD34-expression was demonstrated as a poor prognosis factor of adult patients with AML in most previous reports. The strike immunophenotype of NPM1m+AML is regarded as lacking expression of CD34, which accounts for about 75% patients. Whether CD34-expression on the blasts has independent prognostic value in NPM1-m+AML has yet to be clarified. We therefore systematically evaluated the prognostic relevance of CD34 status in the context of NPM1mutation status and clinical features in 71 patients treated at our institution. Methods: Seventy-one NPM1m+AML patients were retrospectively analyzed in our center. Immunophenotype of AML were detected by 4 color flow cytometry. NPM1 mutation and FLT3-mutation were detected by PCR. Results: The percentage of CD34-expressed blasts of bone marrow ranged from 0.01% to 93.2%. Patients with CD34 expression>7%(according to ROC analysis) had a lower complete remission(CR) rate after 1 course induction, disease-free survival(DFS) and overall survival(OS) compared those with CD34-expression¡Ü7%(CR, 46.4% vs. 81.4%, p=0.0038; 3 years DFS, 26.2% vs. 68.5%, p=0.001; 3 years OS, 24.4% vs.69.1%, p<0.0001). Multivariate analysis revealed CD34-expression as an independent prognostic factor independent of FlT3-ITD for relapse, DFS and OS. We established a new prognostic model based on CD34 and FLT3 status at diagnosis, which could allow dissection of NPM1m+AML into prognostically different three subgroups: CD34>7% and FLT3-ITD, CD34>7%or FLT3-ITD, CD34¡Ü7% and FLT3-WT(3 years DFS of 0 vs. 58.3% vs. 77%, p=0.002; OS of 0 vs. 59.1% vs. 79.9%, p<0.0001 ) . Conclusions: We demonstrated for the first time, that CD34-expression on the blasts is a novel poor predictor independent of FlT3-ITD in patients with NPM1-mutation, and established a new prognostic model based on CD34 and FLT3 status at diagnosis, which could allow immediate clinical utility for prognostic stratification and risk-adapted therapeutic choices. Disclosures: No relevant conflicts of interest to declare.

Relationship Between Clinical Prognosis and Expression of P170 and CD34 in Patients with Preliminary Diagnostic Acute Myeloblastic Leukemia

Evaluation of the expression of CD200 and CD56 in CD34-positive adult acute myeloid leukemia and its effect on the response to induction of chemotherapy

Expression Characteristics and Prognosissignificance of Mirna-181A in Acute Myeloid Leukemia with Normal Karyotype

MiR-362-5p As a Novel Prognostic Predictor of Cytogenetically Normal Acute Myeloid Leukemia

FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

[Prognostic Significance of the Percentage of Blasts with CD34+/CD38low/-/CD123+ Phenotype in Acute Myeloid Leukemias]

High Expression of Mir-25 Predicts Favorable Chemotherapy Outcome in Patients with Acute Myeloid Leukemia.

Cd34 Expression on the Blasts of Bone Marrow is A Novel Predictor of Poor Prognosis Independent of Flt3-Itd in Acute Myeloid Leukemia with Npm1-Mutation

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

CD34 Expression on Bone Marrow Blasts is a Novel Predictor of Poor Prognosis Independent of FlT3-ITD in Acute Myeloid Leukemia with the NPM1-mutation.

The Clinical Significance of Fms-Like Tyrosine Kinase3 Expression for Evaluating the Prognosis of Acute Myeloid Leukemia

[Expressions of CD117 and CD11b in Patients with APL at Diagnosis and Post-Treatment].

Expression of CD56 in acute leukemia and its clinical significance]

High Expression of Mir-363 Predicts Poor Prognosis and Guides Treatment Selection in Acute Myeloid Leukemia

Analysis of Relationship Between Immunophenotype and Prognosis of Acute Leukemia

CD34-Negative is Highly Associated with T (15;17), T (V; 11q23) and the NPM1-Mutation Subtypes in 343 Newly Diagnosed Patients with Acute Myeloid Leukemia

Higher Level of Peripheral Blood CD34 Positive Cells Presented with Unfavorable Prognosis in Intermediate-Low Risk Acute Promyelocytic Leukemia

Expression of p53 Protein in Acute Myeloid and Lymphoblastic Leukemia: Correlation with Induction Treatment Outcome

Clinical Features and Prognosis of 227 cases of Acute Myeloid Leukemia with Cross-lineage Antigen Expression

[Relationship of Immunophenotypic Features with Minimal Residual Disease Detection and Gene Types in 221 Cases of Acute Promyelocytic Leukemia].